Last Updated on February 5, 2021 by The Health Master
Glenmark Pharma has received final approval from the US health regulator for Topiramate extended-release capsules, used to treat certain types of seizures.
The approved product is a generic version of Qudexy capsules of Upsher-Smith Laboratories.
The company has received final approval from the United States Food and Drug Administration (USFDA) for Topiramate extended-release capsules USP in the strengths of 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg, Glenmark said in a regulatory filing.
Quoting IQVIA sales data for the 12-month period ended December 2020, Glenmark Pharmaceuticals said Qudexy extended-release capsules market achieved annual sales of approximately US $120 million.
The company’s current portfolio consists of 169 products authorised for distribution in the US market and 43 abbreviated new drug applications (ANDAs) pending approval with the US FDA.
Also read:
Granules India gets USFDA nod for Potassium Chloride Oral Solution
Glenmark gets USFDA nod for Amphetamine Sulfate tablets
Unichem gets USFDA nod for Zonisamide Capsules
The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.
Follow and connect with us on Facebook and Linkedin
Go to main website, click here
Subscribe for daily free updates, click here
For daily free updates on WhatsApp, click here
